Oncolytics Biotech (TSE:ONC) Stock Price Up 11.8% - Should You Buy?

Oncolytics Biotech Inc. (TSE:ONC - Get Free Report)'s stock price traded up 11.8% during trading on Friday . The company traded as high as C$1.42 and last traded at C$1.42. 428,642 shares traded hands during mid-day trading, an increase of 650% from the average session volume of 57,148 shares. The stock had previously closed at C$1.27.

Analysts Set New Price Targets

Separately, Raymond James boosted their price target on Oncolytics Biotech from C$3.00 to C$3.50 in a research note on Friday, September 20th.

Oncolytics Biotech Stock Up 17.3 %

The company has a quick ratio of 8.86, a current ratio of 4.99 and a debt-to-equity ratio of 6.09. The stock has a market capitalization of C$114.52 million, a P/E ratio of -3.68 and a beta of 1.38. The company has a fifty day moving average price of C$1.31 and a 200-day moving average price of C$1.41.

Oncolytics Biotech (TSE:ONC - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The company reported C($0.10) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of C($0.10). As a group, research analysts forecast that Oncolytics Biotech Inc. will post -0.41 EPS for the current fiscal year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.